

ViroGates notice to convene the annual general meeting 2019

Notice for the annual general meeting of ViroGates A/S, CVR no. 25 73 40 33, is hereby given.

Time: Thursday, 25 April 2019, 5:00 PM

Place: Comwell Holte, Kongevejen 495A, 2840 Holte

Agenda

1. Election of chairman of the meeting
2. The board's report on the Company's business in the past year
3. Submission of the annual report with auditor's report for approval
4. Proposal from the board regarding the distribution of the result in accordance with the approved annual report
5. Election of directors and alternates and remuneration
6. Election of auditor
7. Any other business

Full proposals

Ad pkt. 1

The board proposes that attorney-at-law Nicolai Jung be elected chairman.

Ad pkt. 2

The report is given by the chairman of the board and the Company's CEO.

Ad pkt. 3

The board submits the annual report for approval.

Ad pkt. 4

The board proposes that the year's loss of DKK 16,986,212 is transferred to the next year by application against the transferred result.

Ad pkt. 5

The current board is proposed to be re-elected and it is proposed that no alternates be elected.

It is proposed that the remuneration for the work of the board in 2019 unchanged be fixed at DKK 150,000 to the chairman and DKK 75,000 to each of the other directors.

Ad pkt. 6

The board proposes that BDO Statsautoriseret Revisionsaktieselskab be re-elected.

Ad pkt. 7

No resolutions can be made under this item.

Other information

The right to attend and vote at a general meeting may be exercised by shareholders who are registered in the share register on the record date or who have announced and documented their acquisition of shares for the purpose of registration in the share register by the record date. The record date is **Thursday, 18 April 2019**.

A shareholder or a proxy may attend the annual general meeting together with an adviser.

Proxy

Shareholders unable to attend the annual general meeting may choose to grant a proxy to the Board of Directors or to a named third party.

Proxies can be granted:

- digitally via the investor portal on the Company's website, www.virogates.com, or via VP Investor Services A/S' website, www.vp.dk/agm, or
- by completing, signing and returning the proxy form to VP Investor Services A/S, by post to Weidekampsgade 14, DK-2300 Copenhagen S, by email to vpinvestor@vp.dk.
The proxy form may be downloaded from the Company's website, www.virogates.com.

Proxy forms must be received by VP Investor Services A/S no later than **Wednesday, 24 April 2019**, or be brought along in hard copy to the general meeting.

Votes by correspondence

Shareholders unable to attend the annual general meeting may vote by correspondence. Votes by correspondence cannot be withdrawn.

Votes by correspondence can be sent:

- digitally via the InvestorPortal on the Company's website, www.virogates.com, or via VP Investor Services A/S' website, www.vp.dk/agm, or
- by completing, signing and returning the correspondence voting form to VP Investor Services A/S, by post to Weidekampsgade 14, DK-2300 Copenhagen S, by email to vpinvestor@vp.dk. The correspondence voting form may be downloaded from the Company's website, www.virogates.com.

Correspondence voting forms must be received by VP Investor Services A/S no later than **Wednesday, 24 April 2019**.

Please note that either a proxy or a vote by correspondence may be submitted, but not both.

Additional information

Until and including the day of the annual general meeting, additional information regarding the annual general meeting will be available on the Company's website, www.virogates.com:

- Notice to convene the annual general meeting with agenda, complete proposals and appendices.
- Documents to be presented at the annual general meeting, including the Annual Report 2018
- Information about the total number of shares and voting rights on the date of notice to convene
- Proxy and correspondence voting forms

Entry to the annual general meeting is possible from 4:30 PM. Light refreshments will be served after the meeting.

For further information contact:

CEO Jakob Knudsen

Tel. (+45) 2113 1336, Email: jk@virogates.com

Certified Advisor

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se

About ViroGates

ViroGates is an international Medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage and TurbiLatex test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 550 clinical trials and studies which included more than 300,000 blood samples.